Frontiers in pharmacology · 2025
Glutaredoxin2 reduces age-associated B cell differentiation through maintaining redox homeostasis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Yuan, Sun Chunli, He Qilin, Liu Shujun, Tian Shihao, Zhang Yan, Du Yatao, Li Fubin, Zhang Huihui
Аннотация
BACKGROUND: The redox system plays a pivotal role in autoimmune diseases and cancer, with oxidative stress and antioxidant adaptations driving pathological processes. Age/autoimmunity-associated B cells (ABCs), characterized by elevated ROS levels, are implicated in autoimmune disorders such as systemic lupus erythematosus (SLE). However, the mechanisms linking ROS to ABC differentiation remain unclear. Glutaredoxin 2 (Grx2), a key oxidoreductase, regulates redox homeostasis, but its role in autoimmune B cell biology is underexplored.
METHODS: Using wild-type and Grx2-knockout mice, we examined ROS levels and ABC differentiation. In vitro, ABC differentiation was induced with IL-21 and TLR7 agonist, and the effect of the antioxidant N-Acetyl-L-Cysteine (NAC) was assessed. The SLE-prone ShipΔB model crossed with Grx2-/- mice was used to evaluate autoimmune pathology.
RESULTS: ABCs exhibited higher ROS levels than follicular B cells, and NAC reduced ABC differentiation rate by 50%, demonstrating ROS dependency. Grx2 deficiency amplified ROS levels and ABC proportions in aged mice, correlating with accelerated autoimmunity. In ShipΔB mice, Grx2 deletion exacerbated ABC differentiation, CD4+ T cell activation, and anti-dsDNA autoantibody titers.
CONCLUSIONS: Grx2 acts as a redox checkpoint that limits ABC-driven autoimmunity by modulating ROS. The Grx2-ROS axis represents a potential therapeutic target for SLE and related chronic inflammatory diseases.
METHODS: Using wild-type and Grx2-knockout mice, we examined ROS levels and ABC differentiation. In vitro, ABC differentiation was induced with IL-21 and TLR7 agonist, and the effect of the antioxidant N-Acetyl-L-Cysteine (NAC) was assessed. The SLE-prone ShipΔB model crossed with Grx2-/- mice was used to evaluate autoimmune pathology.
RESULTS: ABCs exhibited higher ROS levels than follicular B cells, and NAC reduced ABC differentiation rate by 50%, demonstrating ROS dependency. Grx2 deficiency amplified ROS levels and ABC proportions in aged mice, correlating with accelerated autoimmunity. In ShipΔB mice, Grx2 deletion exacerbated ABC differentiation, CD4+ T cell activation, and anti-dsDNA autoantibody titers.
CONCLUSIONS: Grx2 acts as a redox checkpoint that limits ABC-driven autoimmunity by modulating ROS. The Grx2-ROS axis represents a potential therapeutic target for SLE and related chronic inflammatory diseases.